We thank Franshaw et al. for expressing their concern about the palbociclib doses used in our preclinical study for DIPG [1] . We are also pleased to see growing interest in fighting this incurable disease.
Franshaw et al pointed out that the dose of palbociclib we used to treat the DIPG xenograft mouse models was much higher than the equivalent maximum tolerated dose (MTD) for humans established based on a Phase I trial. Our goal of the study was to examine whether CDK4/6 is a worthy target for high grade treatment-naïve H3.3-K27 M mutant DIPG. As the blood brain barrier (BBB) of brainstem is relatively intact [2, 3] , higher starting dose of the drug would be needed to deliver similar dose to the pons than to other tissues. According to our literature search, the doses of palbociclib used in preclinical cancer studies in xenograft mouse models, ranged from 12.5 to 150 mg/kg (Table 1) . Therefore, we chose 150 mg/kg in order to deliver sufficient concentration of drug to the pons.
Our study has provided strong evidence that sufficient concentration of palbociclib could be a potential drug for DIPG therapy. To alleviate the toxicity caused by high doses of palbociclib, different drug delivery systems such as Convection Enhanced Delivery (CED) should be tried to lower the drug doses [4] . Furthermore, as we and others pointed out that palbociclib alone is unlikely to have durable effects for a complex disease like DIPG, searching for combination therapy of palbociclib with other drugs should be encouraged [5] . 1 These authors contributed equally. 
